Largest pharmaceutical companies in the United States by total liabilities
Everything the company owes, as its balance sheet stood at the end of the latest fiscal year.
AbbVie leads the 44 pharmaceutical companies in the United States ranked by total liabilities, at SGD 176.9B, ahead of Pfizer (SGD 156.5B) and Johnson & Johnson (SGD 151.7B). Figures as of 20 Nov 2026, 10:45 UTC, from Yahoo Finance quotes.
Key facts
- Companies ranked
- 44
- First
- AbbVieSGD 176.9B
- Median
- SGD 1.1B
- Combined market value
- SGD 4.82T
- Countries
- 1
Market values as of .
United States▾
All sectors▾
Pharmaceuticals▾
| # | Company | Total liabilities ↓ | Market cap | Price | Today | 1 year | Price, 30 days | Country |
|---|---|---|---|---|---|---|---|---|
| 1 | AbbVieABBV · Health Care | SGD 176.9B | SGD 646.3B | SGD 365.64 | 0.86% down | 25% up | ||
| 2 | PfizerPFE · Health Care | SGD 156.5B | SGD 202.4B | SGD 35.51 | 1.85% down | 15% up | ||
| 3 | Johnson & JohnsonJNJ · Health Care | SGD 151.7B | SGD 829.3B | SGD 344.50 | 2.04% down | 34% up | ||
| 4 | Eli LillyLLY · Health Care | SGD 110.8B | SGD 1.55T | SGD 1,742.36 | 2.29% down | 33% up | ||
| 5 | Merck & CoMRK · Health Care | SGD 108.6B | SGD 422.2B | SGD 171.27 | 3.61% down | 45% up | ||
| 6 | Bristol-Myers SquibbBMY · Health Care | SGD 92.2B | SGD 153.8B | SGD 75.23 | 2.05% down | 30% up | ||
| 7 | Abbott LaboratoriesABT · Health Care | SGD 43.8B | SGD 232B | SGD 133.95 | 0.58% down | 16% down | ||
| 8 | ViatrisVTRS · Health Care | SGD 29B | SGD 29.4B | SGD 25.64 | 1.97% down | 99% up | ||
| 9 | ZoetisZTS · Health Care | SGD 15.7B | SGD 42.3B | SGD 104.18 | 5.59% down | 26% down | ||
| 10 | Royalty PharmaRPRX · Health Care | SGD 12.8B | SGD 50.2B | SGD 87.33 | 1.38% down | 79% up | ||
| 11 | Regeneron PharmaceuticalsREGN · Health Care | SGD 12B | SGD 123.2B | SGD 1,190.71 | 2.35% down | 28% up | ||
| 12 | Vertex PharmaceuticalsVRTX · Health Care | SGD 9B | SGD 170.2B | SGD 671.43 | 2.94% down | 27% up | ||
| 13 | Elanco Animal HealthELAN · Health Care | SGD 8.8B | SGD 16.9B | SGD 33.90 | 1.54% down | 26% up | ||
| 14 | Alnylam PharmaceuticalsALNY · Health Care | SGD 5.4B | SGD 25.5B | SGD 190.62 | 1.06% down | 66% down | ||
| 15 | Amneal PharmaceuticalsAMRX · Health Care | SGD 4.7B | SGD 9.6B | SGD 27.58 | 2.24% down | 90% up | ||
| 16 | PTC TherapeuticsPTCT · Health Care | SGD 4B | SGD 6.3B | SGD 75.21 | 3.16% down | 21% down | ||
| 17 | Ionis PharmaceuticalsIONS · Health Care | SGD 3.9B | SGD 5.8B | SGD 35.10 | 0.62% down | 63% down | ||
| 18 | BridgeBio PharmaBBIO · Health Care | SGD 3.9B | SGD 19.6B | SGD 100.82 | 0.22% up | 21% up | ||
| 19 | CytokineticsCYTK · Health Care | SGD 2.7B | SGD 9.2B | SGD 66.36 | 0.27% up | 19% down | ||
| 20 | InsmedINSM · Health Care | SGD 2B | SGD 40.9B | SGD 186.29 | 20.58% up | 40% down | ||
| 21 | BioMarin PharmaceuticalBMRN · Health Care | SGD 1.9B | SGD 15.3B | SGD 79.21 | 0.02% down | 17% up | ||
| 22 | Arrowhead PharmaceuticalsARWR · Health Care | SGD 1.1B | SGD 8B | SGD 56.29 | 1.25% up | 13% up | ||
| 23 | United TherapeuticsUTHR · Health Care | SGD 1B | SGD 30.7B | SGD 721.00 | 3.16% down | 22% up | ||
| 24 | Legend BiotechLEGN · Health Care | SGD 943.4M | SGD 4B | SGD 20.76 | 0.92% down | 41% down | ||
| 25 | Madrigal PharmaceuticalsMDGL · Health Care | SGD 847.1M | SGD 11.9B | SGD 511.62 | 0.34% down | 27% down | ||
| 26 | Axsome TherapeuticsAXSM · Health Care | SGD 775.7M | SGD 9.2B | SGD 174.97 | 1.25% up | 6% down | ||
| 27 | Ligand PharmaceuticalsLGND · Health Care | SGD 700.8M | SGD 7.4B | SGD 370.03 | 3.94% down | 50% up | ||
| 28 | Mirum PharmaceuticalsMIRM · Health Care | SGD 681.1M | SGD 8B | SGD 123.17 | 3.27% up | 34% up | ||
| 29 | Travere TherapeuticsTVTX · Health Care | SGD 632.4M | SGD 6B | SGD 62.29 | 3.86% down | 45% up | ||
| 30 | TG TherapeuticsTGTX · Health Care | SGD 535.5M | SGD 12.6B | SGD 83.67 | 1.88% down | 117% up | ||
| 31 | Cogent BiosciencesCOGT · Health Care | SGD 388.5M | SGD 6.2B | SGD 35.77 | 0.25% down | 20% down | ||
| 32 | Rhythm PharmaceuticalsRYTM · Health Care | SGD 271M | SGD 10.4B | SGD 150.62 | 1.88% down | 18% up | ||
| 33 | Corcept TherapeuticsCORT · Health Care | SGD 243.5M | SGD 9.2B | SGD 83.80 | 4.15% down | 10% down | ||
| 34 | Definium TherapeuticsDFTX · Health Care | SGD 139M | SGD 5.2B | SGD 38.02 | 1.24% up | 168% up | ||
| 35 | Summit TherapeuticsSMMT · Health Care | SGD 119.1M | SGD 10.9B | SGD 13.63 | 0.67% up | 36% down | ||
| 36 | ErascaERAS · Health Care | SGD 91.5M | SGD 6.4B | SGD 18.34 | 3.34% up | 395% up | ||
| 37 | Spyre TherapeuticsSYRE · Health Care | SGD 80.7M | SGD 12B | SGD 125.90 | 3.77% down | 332% up | ||
| 38 | Praxis Precision MedicinesPRAX · Health Care | SGD 77.1M | SGD 11.2B | SGD 400.93 | 1.87% up | 86% up | ||
| 39 | Protagonist TherapeuticsPTGX · Health Care | SGD 69M | SGD 10.4B | SGD 159.93 | 2.47% down | 51% up | ||
| 40 | Dianthus TherapeuticsDNTH · Health Care | SGD 48.4M | SGD 6.2B | SGD 109.39 | 1.01% up | 108% up | ||
| 41 | Edgewise TherapeuticsEWTX · Health Care | SGD 39.1M | SGD 5.8B | SGD 53.09 | 0.48% down | 86% up | ||
| 42 | Oruka TherapeuticsORKA · Health Care | SGD 21.5M | SGD 8.5B | SGD 125.82 | 1.91% up | 255% up | ||
| 43 | Belite BioBLTE · Health Care | SGD 13M | SGD 7.9B | SGD 194.75 | 3.33% down | 43% up | ||
| 44 | VeradermicsMANE · Health Care | SGD 11.8M | SGD 6.8B | SGD 160.41 | 0.38% down | 231% up |
Sources: share prices and market values from Yahoo Finance; sector, country and category from each company's SEC registration; annual figures from the reports companies file with the SEC.
Market value is share price × shares outstanding, from Yahoo Finance; prices may be delayed 15 minutes or more and the ranking refreshes about every 20 minutes. The list covers companies with shares listed in the US, which includes foreign companies listed through ADRs but not ones listed only abroad. Sector, category and country come from each company's SEC registration. Total liabilities is from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day, not of the period. Where a company reports no total-liabilities line, it is worked out as assets less equity. Sums are converted from US dollars at today's exchange rate (1 USD = 1.2896 SGD).
Questions and answers
Which pharmaceutical companies in the United States rank first by total liabilities?
AbbVie (SGD 176.9B), Pfizer (SGD 156.5B) and Johnson & Johnson (SGD 151.7B) are the top three of the 44 pharmaceutical companies in the United States ranked by total liabilities as of 20 Nov 2026, 10:45 UTC.
How many pharmaceutical companies in the United States are in this ranking?
44 are ranked by total liabilities.
What are these pharmaceutical companies in the United States worth together?
The 44 pharmaceutical companies in the United States ranked by total liabilities have a combined market value of SGD 4.82T as of 20 Nov 2026, 10:45 UTC.
What does ranking by total liabilities measure?
Everything the company owes, as its balance sheet stood at the end of the latest fiscal year.
Learn how this ranking works
All markets guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Market cap vs enterprise value: what is the difference?
Market capitalization is the value of a company's shares. Enterprise value is market cap plus debt, minus cash: roughly what it would cost to buy the whole business and settle its borrowings. Two companies with the same $50 billion market cap can have very different enterprise values if one owes $20 billion and the other holds $20 billion in cash.
- How an ETF's size is measured: AUM, NAV and creation units
An ETF's size is usually measured by its assets under management (AUM), the fund's net assets: everything it holds minus what it owes. That equals net asset value per share times shares outstanding. AUM grows when the holdings rise in value and when large institutions create new shares, and shrinks when they redeem them.
Cite this page
Funkfolio, “Largest pharmaceutical companies in the United States by total liabilities”, data as of 20 November 2026. https://funkfolio.com/companies/category/pharmaceuticals?country=united-states&by=total-liabilities
Underlying data: Yahoo Finance; SEC EDGAR.